Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $63
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $61 to $63.
Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $61 to $63.